The pharmaceutical supply chain is incredibly intricate. Many ingredients are frequently delivered in bulk, repackaged, and reshipped before reaching the maker of branded end-products.
There are frequently many levels of suppliers and wholesalers involved. Borders are often crossed. Labelling is critical for smoothing the flow of the pharmaceutical supply chain because issues might develop at any point along the way or “wait” until a product is finished to appear.
Companies that choose a centralized approach to labelling can link the labelling process with their current ERP, PLM, or other verified systems to drive data from sources of truth, giving them more control. Companies may minimize the need to copy data by employing a single database, which lowers mistakes and improves labelling uniformity for deployment to additional factories and distribution partners throughout the world. As a result, there is a new degree of uniformity, troubleshooting is simplified, and labelling is streamlined, all of which contribute to higher supply chain efficiency.
The Drug Supply Chain Security Act (DSCSA)
The Drug Supply Chain Security Act (DSCSA) is intended to improve traceability by allowing authentic pharmaceuticals to be confirmed, illicit drugs to be identified, and product recalls to be made easier. The DSCSA’s provisions apply to all companies involved in the supply chain, including manufacturers, wholesalers, drug distributors, repackagers, and dispensers. To safeguard providers and patients, and to defend against product mishandling through counterfeiting, gray marketing, and diversion, all parties have responsibilities for protecting the pharmaceutical supply chain.
Enterprise labelling systems
A complete enterprise labelling system enables businesses to quickly adapt to changing regional and international labelling regulations, such as those set out by the DSCSA. Manufacturers may allow labelling variants while reducing the risk of manual mistakes and mislabelling by employing flexible business logic. Using data-driven label content and flexible business logic allows you to swiftly respond to needs while reducing the amount of validation and approval work required to put label changes into production.
Pharmaceutical businesses have been grappling with how to incorporate partners into their operations for years. Many businesses today employ third parties as extensions of their own operations. Companies handle third parties in a variety of ways when it comes to labelling, but it’s typically a manual procedure rife with inefficiencies and difficult to manage consistently at remote sites. Many manufacturers use third-party printing businesses to create and distribute labels directly to their partners, or they pay to have labels produced by an outside vendor once they receive an order. These methods can be very expensive and can result in substantial delays and blunders, especially if you need to comply with ongoing regulations such as the DSCSA. The easiest method to deal with this problem is to incorporate third-party labelling solutions.
Suppliers can access and print labels with the relevant information requested by the receiving business using a secure partner portal or a secure enterprise labelling system. Globally consistent labelling removes the need to manually ship labels around the world and the requirement to relabel inbound shipments, saving time, labour, and money while lowering the risk of mistakes.
Labeling is a complicated procedure, and today’s pharmaceutical businesses are faced with a variety of developing criteria that make it much more complicated, leaving many companies to accept outside modifications and regulatory updates as a cost of doing business. It doesn’t have to be that way, though. Labelling may make a big impact, allowing IT and supply chain decision-makers to overcome obstacles and gain a competitive edge for their firm.